A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain
Interstitial Cystitis
About this trial
This is an interventional treatment trial for Interstitial Cystitis
Eligibility Criteria
Inclusion Criteria: Female patient 18 years of age or older diagnosis of Interstitial Cystitis/Painful Bladder Syndrome, scoring 6 points or higher on O'Leary Sant Questionnaire Exclusion Criteria: Active pelvic or bladder infection within past 2 weeks contraindications to medications or intervention therapeutics inability to speak or read English pelvic floor interventional procedure including bladder instillations 4 weeks prior to study recruitment meets criteria for diagnostic laparoscopy internal referral (to reduce severity bias) Note: patients are not excluded for currently taking any medication on the treatment list. Patients can be treated for UTI during the study period.
Sites / Locations
- Magee Womens HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Multimodal care bundle
Usual care
Components of multimodal care bundle MD Evaluation On site pelvic floor physical therapy Behavioral health consult with appropriate psychiatric referrals/treatments Central sensitization/neurogenic pain: Amitriptyline 10-50mg Or Gabapentin (doses range from 100mg po tid to 600mg po tid) Urinary symptoms IC/PBS: Spasm: Overactive bladder medication chosen based on patient characteristics/insurance, dose may be increased as tolerated (Oxybutynin/Trospium/Detrol vs. Mirabegron) Microbiome: Methenamine Vaginal estrogen At least once within 12 weeks of initial visit: Operative cystoscopy Bladder instillations x 6 weeks (lidocaine, heparin, sodium bicarb, Kenalog, gentamicin) Pudendal/Levator and/or Obturator internus nerve block (120mg Kenalog and 0.25% Marcaine, total 23cc)
IC/PBS treatments as directed by Urogynecology specialist